Financial Snapshot
Revenues
Revenues
Revenue YoY Change
Revenues
Expenses
Cost Of Revenues
Gross Profit
Gross Profit Margin
Gross Profit
Selling, General & Admin Expense
Research & Development
Depreciation, Depletion & Amortization
SGA Expense to Gross Profit Ratio
R&D To Gross Profit Ratio
DDA To Gross Profit Ratio
Operating Expenses Total
Operating Profits/Loss
Operational Expenses
Interest Expenses
Interest Expenses To Operating Income %
Other Expense/Income
Interest & Other Expense/Income
Income/Loss
Pretax Income
Income Tax
Net Profits/Loss
Pretax Income YoY Change
Income Tax Rate
Net Profits/Loss YoY Change
Basic EPS
Net Income To Revenue Ratio
Pretax & Net Income
Assets & Liabilities
Cash & Short-Term Investments
Cash & Equivalents
Cash To Operating Expenses Ratio
Inventory
Receivables
Total Short-Term Assets
Property, Plant And Equipment
Long-Term Investments
Total Long-Term Assets
Total Assets
Net Income To Total Assets Percentage
Accounts Payable
Short-Term Debt
Long Term Debt Due
Total Short-Term Liabilities
Long-Term Debt
Other Long-Term Liabilities
Total Long-Term Liabilities
Total Liabilities
Short-Term To Long-Term Debt Ratio
Short-Term Assets To Debt Ratio
Long-Term Debt To Net Income Ratio
Assets & Liabilities
Ownership
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares
Stock Issuance & Repurchase
Ownership Data
Return On Shareholders' Equity
Book Value
Free Cash Flow
Free Cash Flow YoY
Free Cash Flow Margin
Dividends
Dividends
Stock Price
About IPI Legacy Liquidation Co
Impel Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The company is headquartered in Seattle, Washington and currently employs 160 full-time employees. The company went IPO on 2021-04-23. The firm has designed its Precision Olfactory Delivery (POD) technology to target the vascular-rich upper nasal space, and to provide rapid absorption, consistent drug biodistribution and ease of use for a patient, provider, or caregiver. The Company’s product, Trudhesa, is a liquid formulation of dihydroergotamine (DHE), administered to the upper nasal space using its proprietary POD technology for the acute treatment of migraine headaches with or without aura in adults. The firm is developing its product candidate, INP105, as an upper nasal formulation of olanzapine administered using its POD technology for the treatment of agitation and aggression associated with autism spectrum disorder (ASD).
Industry: Pharmaceutical Preparations Peers: CAPRICOR THERAPEUTICS, INC. Celcuity Inc. PARDES BIOSCIENCES, INC. Icosavax, Inc. Matinas BioPharma Holdings, Inc. Ovid Therapeutics Inc. PRECISION BIOSCIENCES INC Tenaya Therapeutics, Inc. Werewolf Therapeutics, Inc.
